The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Single dose NTBC‐treatment of hereditary tyrosinemia type I
Abstract
NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3cyclohexanedione) is the mainstay of treatment in tyrosinemia type 1 (HT 1). The current recommendation is to divide the total daily dose of NTBC into two doses. We monitored the plasma NTBC concentrations in a series of seven patients who were changed from multiple divided doses to a single daily dose of NTBC. Two additional patients were started on a single daily dose of NTBC after the diagnosis of HT 1 was established. In three patients, NTBC kinetics were performed over 6 and 24 hours, respectively. The use of multiple divided doses or a single daily dose did not significantly affect plasma NTBC concentrations or the mean daily dose needed to attain therapeutic plasma NTBC concentrations. Moreover, kinetic studies demonstrated that plasma NTBC concentrations were completely stable over a period of 24 hours with a single dose regimen, as expected given the known NTBC plasma half life of 54 hours. Although these preliminary results need to be confirmed in more patients, our findings show that administration of NTBC in a single daily dose may be as effective as a multiple‐dose regimen in reaching therapeutic plasma NTBC concentrations and suppressing succinylacetone formation in patients with HT 1. In fact, single dose treatment may increase patients’ compliance with the drug treatment and improve metabolic control.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“start nitisinone (NTBC, Orfadin®,) in a dose of 1 mg/kg/d once a day as the half life is 54 hrs [19,20].”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [20]
In the citing paper
“On the standard dose of 1 mg/kg/d, the plasma concentrations in individuals that suppress SA are variable [16,20].”
From Recommendations for the management of tyrosinaemia type 1 (2013) · cites this paper as [20]
In the citing paper
“Target levels are not well defined, in the literature, different target levels of NTBC have been suggested [39],[42],[45]-[47].”
From Cross-sectional study of 168 patients with hepatorenal tyrosinaemia and implications for clinical practice (2014) · cites this paper as [42]
Citations
Cites
The Metabolic and Molecular Bases of Inherited Disease
Scriver, R. C. (1995) · Medical Entomology and Zoology · Cited by 12,101
The metabolic and molecular bases of inherited disease
Chen, Y.-T. (2001) · Medical Entomology and Zoology · Cited by 6,928
Inborn Metabolic Diseases: Diagnosis and Treatment
(2006) · Springer eBooks · doi:10.1007/978-3-540-28785-8 · Cited by 361
Tyrosinaemia type I and NTBC (2‐(2‐nitro‐4‐trifluoromethylbenzoyl)‐1,3‐cyclohexanedione)
Holme, E., & Lindstedt, S. (1998) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1005410820201 · Cited by 264
NTBC treatment in tyrosinaemia type I: Long‐term outcome in French patients
Masurel‐Paulet, A., Poggi‐Bach, J., Rolland, M. ‐., Bernard, O., Guffon, N., Dobbelaere, D., Sarles, J., de Baulny, H. O., & Touati, G. (2008) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-008-0793-1 · Cited by 212 · cited 3×
“NTBC is well tolerated with few side effects, and its efficacy has well been recognized (Holme and Lindstedt 2000; Joshi and Venugopalan 2004, Masurel-Paulet et al 2008).”
BackgroundNONTRANSPLANT TREATMENT OF TYROSINEMIA
Holme, E., & Lindstedt, S. (2000) · Clinics in Liver Disease · doi:10.1016/s1089-3261(05)70142-2 · Cited by 159
Jorquera, R., & Tanguay, R. M. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.17.1741 · Cited by 136
Hall, M. G., Wilks, M. F., Provan, W. M., Eksborg, S., & Lumholtz, B. (2001) · British Journal of Clinical Pharmacology · doi:10.1046/j.0306-5251.2001.01421.x · Cited by 110 · cited 2×
“Because the NTBC half life is known to be 54 hours (Hall et al 2001), we measured the plasma NTBC concentrations in a total of nine patients who were given NTBC as a single daily dose: seven patients were changed frommultiple daily doses to a single dose and two patients were started on a single…”
MethodResultVisceral pathology of hereditary tyrosinemia type I.
Russo, P., & O’Regan, S. (1990) · Europe PMC (PubMed Central) · Cited by 101
Physician’s Guide to the Treatment and Follow-Up of Metabolic Diseases
Blau, N., Leonard, J. V., Hoffmann, G. F., & Clarke, J. T. R. (2006) · Springer eBooks · doi:10.1007/3-540-28962-3 · Cited by 91
Research works printed but not linked: 1
- Orfadin [package insert], 2010, Swedish Orphan Biovitrium International AB
Cited by
Chinsky, J. M., Singh, R., Ficicioglu, C., van Karnebeek, C. D. M., Grompe, M., Mitchell, G., Waisbren, S. E., Gucsavas-Calikoglu, M., Wasserstein, M. P., Coakley, K., et al. (2017) · Genetics in Medicine · doi:10.1038/gim.2017.101 · Cited by 247
Recommendations for the management of tyrosinaemia type 1
de Laet, C., Dionisi-Vici, C., Leonard, J. V., McKiernan, P., Mitchell, G., Monti, L., de Baulny, H. O., Pintos-Morell, G., & Spiekerkötter, U. (2013) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-8-8 · Cited by 227
Self-citationMayorandan, S., Meyer, U., Gokcay, G., Segarra, N. G., de Baulny, H. O., van Spronsen, F., Zeman, J., de Laet, C., Spiekerkoetter, U., Thimm, E., et al. (2014) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-014-0107-7 · Cited by 131
“[42] advocating once daily dosing sheds some indirect light on the pharmacokinetics of NTBC in children.”
Self-citation
Metadata
- Authors
- Schlune, A., Thimm, E., Herebian, D., & Spiekerkoetter, U.
- Affiliations
- Düsseldorf University Hospital (DE)
- Corresponding author
- Schlune, A.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2012-02-04
- Volume
- 35
- Issue
- 5
- Pages
- 831-836
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2041258761
- Cited by
- 33
- References
- 22
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 2 · 2022: 2 · 2021: 1 · 2020: 6 · 2019: 2 · 2018: 4 · 2017: 5 · 2015: 2 · 2014: 4 · 2013: 3
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Inherited Metabolic Disease (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Health Sciences › Medicine › Genetics (clinical) › Lysosomal Storage Disorders Research
- Keywords
- NTBC, tyrosinemia type I, once-daily dosing, dosing regimen, pharmacokinetics, succinylacetone, medication adherence, metabolic control
- MeSH terms
- Cyclohexanones, Drug Administration Schedule, Female, Heptanoates, Humans, Infant, Infant, Newborn, Male, Nitrobenzoates, Tyrosinemias
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Single dose NTBC‐treatment of hereditary tyrosinemia type I. https://app.cochat.ai/papers/10.1007/s10545-012-9450-9
- The paper
- Schlune, A., Thimm, E., Herebian, D., & Spiekerkoetter, U. (2012). Single dose NTBC‐treatment of hereditary tyrosinemia type I. Journal of Inherited Metabolic Disease. https://doi.org/10.1007/s10545-012-9450-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.